Table 2 Correlations between the M1 and M2 TAMs infiltration levels and the clinicopathologic characteristics of LSCC (intra-groups analysis)
Features | Cases | TS iNOS + M1 TAM count | p-value | TN CD206 + M2 TAM count | p-value | TS CD206 + M2 TAM count | p-value | TS CD206 + M2 TAM count | p-value | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Yes | No | Â | Yes | No | Â | Yes | No | Â | High | Low | Â | ||
N = 13 (N,%) | N = 67 (N,%) | N = 28 (N,%) | N = 52 (N,%) | N = 53 (N,%) | N = 27 (N,%) | N = 27 (N,%) | N = 26 (N,%) | ||||||
Age | Â | Â | Â | 0.366 | Â | Â | 0.602 | Â | Â | 0.466 | Â | Â | 0.016 |
  < 65 | 46 | 6 (13.0) | 40 (87.0) |  | 15 (32.6) | 31 (67.4) |  | 32 (69.6) | 14 (30.4) |  | 12 (37.5) | 20 (62.5) |  |
  ≥ 65 | 34 | 7 (20.6) | 27 (79.4) |  | 13 (38.2) | 21 (61.8) |  | 21 (61.8) | 13 (38.2) |  | 15 (71.4) | 6 (28.6) |  |
Smoking history | Â | Â | Â | 0.209 | Â | Â | 0.082 | Â | Â | 0.135 | Â | Â | 0.094 |
 No | 24 | 2 (8.3) | 22 (91.7) |  | 5 (20.8) | 19 (79.2) |  | 13 (54.2) | 11 (45.8) |  | 4 (30.8) | 9 (69.2) |  |
 Yes | 56 | 11 (19.6) | 45 (80.4) |  | 23 (41.1) | 33 (58.9) |  | 40 (71.4) | 16 (28.6) |  | 23 (57.5) | 17 (42.5) |  |
Alcohol drinking | Â | Â | Â | 0.221 | Â | Â | 0.981 | Â | Â | 0.808 | Â | Â | 0.328 |
 No | 37 | 4 (10.8) | 33 (89.2) |  | 13 (35.1) | 24 (64.9) |  | 24 (64.9) | 13 (35.1) |  | 14 (58.3) | 10 (41.7) |  |
 Yes | 43 | 9 (20.9) | 34 (79.1) |  | 15 (34.9) | 28 (65.1) |  | 29 (67.4) | 14 (32.6) |  | 13 (44.8) | 16 (55.2) |  |
Primary site | Â | Â | Â | 0.222 | Â | Â | 0.683 | Â | Â | 0.822 | Â | Â | 0.865 |
 Glottic | 49 | 6 (12.2) | 43 (87.8) |  | 18 (36.7) | 31 (63.3) |  | 32 (65.3) | 17 (34.7) |  | 16 (50.0) | 16 (50.0) |  |
 Supraglottic | 31 | 7 (22.6) | 24 (77.4) |  | 10 (32.3) | 21 (67.7) |  | 21 (67.7) | 10 (32.3) |  | 11 (52.4) | 10 (47.6) |  |
T stage | Â | Â | Â | 0.502 | Â | Â | 0.466 | Â | Â | 0.098 | Â | Â | 0.761 |
 T12 | 18 | 2 (11.1) | 16 (88.9) |  | 5 (27.8) | 13 (72.2) |  | 9 (50.0) | 9 (50.0) |  | 5 (55.6) | 4 (44.4) |  |
 T34 | 62 | 11 (17.7) | 51 (82.3) |  | 23 (37.1) | 39 (62.9) |  | 44 (71.0) | 18 (29.0) |  | 22 (50.0) | 22 (50.0) |  |
N stage | Â | Â | Â | 0.083 | Â | Â | 0.293 | Â | Â | 0.562 | Â | Â | 0.646 |
 N0 | 48 | 5 (10.4) | 43 (89.6) |  | 19 (39.6) | 29 (60.4) |  | 33 (68.8) | 15 (31.2) |  | 16 (48.5) | 17 (51.5) |  |
 N +  | 32 | 8 (25.0) | 24 (75.0) |  | 9 (28.1) | 23 (71.9) |  | 20 (62.5) | 12 (37.5) |  | 11 (55.0) | 9 (45.0) |  |
Pathological stage | Â | Â | 0.423 | Â | Â | 0.723 | Â | Â | 0.022 | Â | Â | 0.685 | |
 Stage I-III | 45 | 6 (13.3) | 39 (86.7) |  | 15 (33.3) | 29 (66.7) |  | 25 (55.6) | 20 (44.4) |  | 12 (48.0) | 13 (52.0) |  |
 Stage IV | 35 | 7 (20.0) | 28 (80.0) |  | 13 (37.1) | 23 (62.9) |  | 28 (80.0) | 7 (20.0) |  | 15 (53.6) | 13 (46.4) |  |
Tumor differentiation | Â | Â | 0.606 | Â | Â | 0.911 | Â | Â | 0.978 | Â | Â | 0.36 | |
 Well/moderately | 71 | 11 (15.5) | 60 (84.5) |  | 25 (35.2) | 29 (64.8) |  | 47 (66.2) | 24 (33.8) |  | 25 (53.2) | 22 (46.8) |  |
 Poorly | 9 | 2 (22.2) | 7 (77.8) |  | 3 (33.3) | 6 (66.7) |  | 6 (66.7) | 3 (33.3) |  | 2 (33.3) | 4 (66.7) |  |
Recurrence | Â | Â | Â | 0.037 | Â | Â | <0.001 | Â | Â | 0.016 | Â | Â | 0.000 |
 No | 54 | 12 (22.2) | 42 (77.8) |  | 10 (18.5) | 44 (81.5) |  | 31 (57.4) | 23 (42.6) |  | 8 (25.8) | 23 (74.2) |  |
 Yes | 26 | 1 (3.8) | 25 (96.2) |  | 18 (69.2) | 8 (30.8) |  | 22 (84.6) | 4 (15.4) |  | 19 (86.4) | 3 (13.6) |  |
Prognosis | Â | Â | Â | 0.055 | Â | Â | <0.001 | Â | Â | 0.013 | Â | Â | 0.000 |
 Live | 56 | 12 (21.1) | 44 (78.9) |  | 12 (21.1) | 44 (78.9) |  | 33 (57.9) | 23 (42.1) |  | 9 (27.3) | 24 (72.7) |  |
 Died | 24 | 1 (4.3) | 23 (95.4) |  | 16 (69.6) | 8 (30.4) |  | 20 (87.0) | 4 (13.0) |  | 18 (90.0) | 2 (10.0) |  |